Pepro Tech
A more recent version of this article appeared on December 1, 2008

Published online before print July 29, 2008
This Article
Right arrow Full Text (Reprint (PDF))
Right arrow All Versions of this Article:
jlb.0208092v1
84/6/1364    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Santegoets, S. J. A. M.
Right arrow Articles by de Gruijl, T. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Santegoets, S. J. A. M.
Right arrow Articles by de Gruijl, T. D.
© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.0208092

Received for publication February 7, 2008.
Revised June 1, 2008.
Accepted for publication June 2, 2008.

Article

Human dendritic cell line models for DC differentiation and clinical DC vaccination studies

Saskia J. A. M. Santegoets *{dagger}, Alfons J. M. van den Eertwegh {dagger}, Arjan A. van de Loosdrecht {ddagger}, Rik J. Scheper *@, and Tanja D. de Gruijl {dagger}

Departments of *Pathology, {dagger}Medical Oncology, and {ddagger}Hematology, VU University Medical Center, Amsterdam, The Netherlands

@ To whom correspondence should be addressed. E-mail: rj.scheper{at}vumc.nl.


arrow
Abstract

Dendritic cells (DC) are increasingly applied in the immunotherapy of cancer. As the development of a standardized DC vaccine product is often hampered by the limited availability of DC precursors and inter- and intra-donor variability, and the preparation of individual vaccines is labor-intensive, it would be preferable to use DC from a readily available and unlimited source, such as cell lines can provide. It has been described that leukemia-derived cell lines are able to differentiate into functional DC, creating possibilities for the development of highly reproducible DC vaccines and providing in vitro model systems for in-depth studies about DC physiology. This review discusses the different human DC cell line differentiation models described so far. Based on the available data, characteristics that determine the ability of leukemia cells to differentiate along the different precursor stages into functional DC will be formulated. In addition, evidence will be provided that the human CD34+ acute myeloid leukemia cell line MUTZ-3 provides DC that exhibit the functional properties that are crucial for the in vivo generation of CTL-mediated immunity and thus, currently, represents the most valuable, sustainable model system for myeloid DC differentiation and clinical DC vaccination studies.

Key Words: biology • MUTZ-3 • interstitial • Langerhans cell • immunotherapy